Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK.
Scientific Direction, HEOR, Real Life Data, Badalona, Barcelona, Spain.
J Comp Eff Res. 2019 Oct;8(14):1201-1212. doi: 10.2217/cer-2019-0079. Epub 2019 Jul 23.
To compare the risk of stroke, systemic thromboembolism and bleeding, in patients initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation. An observational, retrospective study was performed using medical records of patients who initiated apixaban or acenocoumarol between 2015 and 2017. Propensity score matching was used to match patients; stroke, systemic thromboembolism, major and minor bleeding events were compared between the matched patients. Patients who were prescribed apixaban had a lower rate of systemic embolism/stroke (hazard ratio [HR] = 0.54; 95% CI: 0.38-0.78; p = 0.001), minor bleeding (HR = 0.64; 95% CI: 0.52-0.79; p < 0.001) and major bleeding (HR = 0.51; 95% CI: 0.37-0.72; p < 0.001). Patients prescribed apixaban for the treatment of nonvalvular atrial fibrillation had lower rates of thromboembolic events and minor/major bleeding than patients on acenocoumarol.
比较非瓣膜性心房颤动患者开始使用阿哌沙班或华法林治疗时的卒中、全身性血栓栓塞和出血风险。本研究采用回顾性观察研究方法，使用 2015 年至 2017 年期间开始使用阿哌沙班或华法林的患者的病历进行分析。采用倾向性评分匹配匹配患者；比较匹配患者的卒中、全身性血栓栓塞、大出血和小出血事件。接受阿哌沙班治疗的患者全身性栓塞/卒中发生率较低（风险比[HR] = 0.54；95%置信区间：0.38-0.78；p = 0.001），小出血（HR = 0.64；95%置信区间：0.52-0.79；p < 0.001）和大出血（HR = 0.51；95%置信区间：0.37-0.72；p < 0.001）。接受阿哌沙班治疗的非瓣膜性心房颤动患者的血栓栓塞事件和小出血/大出血发生率低于接受华法林治疗的患者。
